Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency

Ads

You May Also Like

Aduro Biotech to Present at Two Investor Conferences in March

BERKELEY, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced ...

Fluidigm Announces Second Quarter 2018 Financial Results

Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 ...

Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate

MADISON, Wis. and COURBEVOIE, France, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), ...